Limited or Ligand Pharmaceuticals Incorporated is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

JAZZ's acquisition of CMRX is set to add a rare high-grade brain tumor drug currently under the FDA's review. The deal is likely to be closed by June 2024.

Jazz Pharmaceuticals JAZZ has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table encapsulates their recent ...

U.S. stock markets witnessed an impressive rally in 2024 after an astonishing bull run in 2023. Despite fluctuations, the bull run continued in 2025. However, U.S. stocks suffered a blow and the bull ...

Investors generally consider a stock's 52-week high a good criterion for an entry or exit point. Stocks touching new 52-week highs are often predisposed to profit-taking, resulting in pullbacks and ...

Jazz reports better-than-expected fourth-quarter results. Its newly issued EPS guidance of $22.50-$24.00 for full-year 2025 surpasses our expectations.

Management is focused on diversifying its portfolio, with the new drug approvals of Zepzelca (for metastatic small cell lung cancer), Rylaze (for acute lymphoblastic leukemia), Xywav (for the ...

DUBLIN, Feb. 25, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced financial results for the full year and fourth quarter of 2024 and provided guidance for 2025.